MIM
FDMT icon

MetLife Investment Management’s 4D Molecular Therapeutics FDMT Stock Holding History

MetLife Investment Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
26,057
+1,456
+6% +$14.2K ﹤0.01% 2125
2026
Q1 		$229K Sell
24,601
-491
-2% -$4.27K ﹤0.01% 2161
2025
Q4 		$188K Buy
25,092
+6,691
+36% +$67.9K ﹤0.01% 2305
2025
Q3 		$160K Sell
18,401
-15,051
-45% -$90K ﹤0.01% 2436
2025
Q2 		$124K Buy
33,452
+4,707
+16% +$16.5K ﹤0.01% 2432
2025
Q1 		$92.8K Sell
28,745
-6,650
-19% -$31.3K ﹤0.01% 2562
2024
Q4 		$197K Buy
35,395
+6,312
+22% +$49.5K ﹤0.01% 2314
2024
Q3 		$314K Hold
29,083
– – ﹤0.01% 2042
2024
Q2 		$610K Buy
29,083
+7,983
+38% +$200K ﹤0.01% 1611
2024
Q1 		$672K Hold
21,100
– – ﹤0.01% 1524
2023
Q4 		$427K Hold
21,100
– – ﹤0.01% 1787
2023
Q3 		$269K Buy
21,100
+3,721
+21% +$62.2K ﹤0.01% 2022
2023
Q2 		$314K Hold
17,379
– – ﹤0.01% 1984
2023
Q1 		$299K Hold
17,379
– – ﹤0.01% 1962
2022
Q4 		$386K Hold
17,379
– – ﹤0.01% 1811
2022
Q3 		$140K Hold
17,379
– – ﹤0.01% 2500
2022
Q2 		$121K Hold
17,379
– – ﹤0.01% 2626
2022
Q1 		$263K Buy
17,379
+6,197
+55% +$97.3K ﹤0.01% 2178
2021
Q4 		$245K Buy
11,182
+3,203
+40% +$78.5K ﹤0.01% 1931
2021
Q3 		$215K Buy
+7,979
New +$228K ﹤0.01% 2050
2021
Q2 		– Sell
-4,083
Closed -$177K – 2451
2021
Q1 		$177K Buy
+4,083
New +$181K ﹤0.01% 2120

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

MetLife Investment Management's FDMT Position: Q2 2026 in Review

MetLife Investment Management increased its 4D Molecular Therapeutics (FDMT) stake by 5.9% in Q2 2026, buying an estimated $14.2K and bringing the position to 26,057 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #2125.

MetLife Investment Management first reported a position in FDMT in Q1 2021 and has held it in 21 quarters since. The position peaked at $672K in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • MetLife Investment Management held 26,057 shares of 4D Molecular Therapeutics worth $347K as of Q2 2026.
  • MetLife Investment Management bought 1,456 4D Molecular Therapeutics shares in Q2 2026, an estimated $14.2K.
  • 4D Molecular Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2125 holding.
  • MetLife Investment Management first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • MetLife Investment Management's 4D Molecular Therapeutics position peaked at $672K in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.